Table 1.
Clinical characteristics of patients before the treatments
| Characteristics | Group R | Group C | P value |
|---|---|---|---|
| Total number | 49 | 40 | |
| Diseases | |||
| ITP | 30 | 11 | |
| AIHA | 14 | 22 | |
| Evans | 5 | 7 | |
| Sex | |||
| Female | 29 | 26 | .570 |
| Male | 20 | 14 | |
| Age (y) | |||
| 14 ~ 17 | 3 | 0 | |
| 18 ~ 29 | 16 | 3 | |
| 30 ~ 39 | 6 | 8 | |
| 40 ~ 49 | 8 | 8 | |
| 50 ~ 59 | 7 | 17 | |
| 60 ~ 69 | 5 | 3 | |
| 70 ~ 79 | 3 | 0 | |
| ≥80 | 1 | 1 | |
| Median | 38 | 51 | |
| Events during follow‐up | |||
| Autoimmune disease | 10 | 6 | .509 |
| Malignant tumor | 4 | 1 | .489 |
| Liver or kidney dysfunction | 15 | 19 | .103 |
| CD 20 (%) | (n = 45) | (n = 33) | |
| Median (range) | 17.66 (0.48 ~ 52.50) | 18.97 (1.64 ~ 64.74) | .789 |
| Follow‐up time (months) | |||
| Median (range) | 6.0 (1 ~ 54) | 4.0 (2 ~ 36) | .065 |
Abbreviations: AIHA, autoimmune hemolytic anemia; Group C, patients with treatments of cyclophosphamide; Group R, patients with treatments of low‐dose rituximab; ITP, idiopathic thrombocytopenic purpura.